

Making
life better.
Together.

Lilly



LILLY OPEN INNOVATION DRUG DISCOVERY PROGRAM

For scientists. By scientists.


Together we can make a much greater difference than any of us could alone. That's why **Lilly Open Innovation Drug Discovery (OIDD)** is focused on the collaborative efforts that push science forward.

Lilly OIDD was created for scientists, by scientists. We engage external investigators like you in a hypothesis-driven approach to early drug discovery. We give you access to the same tools and expertise available to our scientists. You retain complete control of your intellectual property while still benefitting from the proprietary analysis we provide. And, you can use our tools to design and submit new molecules. So you can keep asking “what if” and explore the possibilities.

WHAT'S IN IT FOR YOU?

- Access to our secure platform, cutting-edge computational tools, *in vitro* biological assays and synthetic technologies.
- Ownership of your submissions and strict confidentiality to protect your intellectual property.
- On-demand status information and publication-quality data.
- The ability to move your science forward by engaging in iterative experimentation.
- Multiple opportunities for your institution to collaborate with Lilly scientists.
- Access to dedicated Lilly experts who can explain your data results in greater detail.
- Control of the process—the decision to take the next step is always yours.





“ We realize it’s important to bring together, through partnership and collaboration, diverse scientific talent and capabilities to find the best possible outcomes for the people we serve. ”

ALAN PALKOWITZ, PH.D.

Vice President, Discovery Chemistry

**1**

DESIGN

We make available a variety of *in silico* design tools that give investigators the power to design molecules with desirable drug-like properties or suitable, specific biological targets.

You get access to sophisticated computational workflows in a private, secure environment in the cloud. Your ideas are never shared with Lilly or Lilly systems without your consent.

**2**

SCREENING

Lilly continues to invest significant resources into the development of *in vitro* screening modules within therapeutic areas of long-standing strategic interest.

By making these proprietary assay modules available to external investigators, we're providing in-kind research capabilities for evaluation and characterization of your compounds. And, you and your institution retain ownership of all generated data and associated intellectual property rights.

**3**

COMPOUND ACQUISITION

Our Compound Acquisition program acquires compounds of interest from those submitted through OIDD to help us add structural diversity to our existing compound collection.

Submitters can potentially earn money for their research while also helping Lilly expand the base of compounds we can study in an effort to advance the science that leads to new drug discovery.



4

SYNTHESIS

Synthesis offers you the opportunity to prepare compounds remotely in our Automated Synthesis Laboratory.

You not only get access to this state-of-the-art equipment, but also to returned material and *in vitro* data from screening. All proposed compounds remain structure-blinded until you select them for synthesis. We encourage you to design and submit a library of compounds.



5


NEGLECTED AND TROPICAL DISEASES

We have standing agreements with global partner agencies that support non-profit research in neglected and tropical diseases.

If one of our partners identifies your compound as a molecule of interest, you may opt to engage directly with that partner. At all times, the decision to work with Lilly or our non-profit partners is entirely yours.

Start the discovery process today.

Go to openinnovation.lilly.com
to learn more about Lilly OIDD.



Start the discovery process today.

Go to **openinnovation.lilly.com**
to learn more about Lilly OIDD.